Economic Burden of Adult Pharyngitis: The Payer's Perspective
Abstract Objectives Although not recommended by practice guidelines, physicians frequently prescribe an antibiotic for adults with viral pharyngitis. The financial burden of this practice, from the payer's perspective, has not been previously evaluated. The purpose of this study was to estimate...
Gespeichert in:
Veröffentlicht in: | Value in health 2008-07, Vol.11 (4), p.621-627 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 627 |
---|---|
container_issue | 4 |
container_start_page | 621 |
container_title | Value in health |
container_volume | 11 |
creator | Salkind, Alan R., MD Wright, Julie M., PharmD |
description | Abstract Objectives Although not recommended by practice guidelines, physicians frequently prescribe an antibiotic for adults with viral pharyngitis. The financial burden of this practice, from the payer's perspective, has not been previously evaluated. The purpose of this study was to estimate those expenditures. Methods A cost-of-illness study was performed to estimate annual expenditures of pharyngitis management from the payer's perspective. National Ambulatory Care Survey data were used to represent current patterns of ambulatory care visits and antibiotic prescriptions for adult pharyngitis. Direct and antibiotic resistance costs were summed to estimate total expenditures for pharyngitis management. Resistance costs were calculated using a model linking the effect of antibiotic consumption to the cost consequences of resistant Streptococcus pneumoniae infection. Sensitivity analyses compared cost outcomes of current practice, adherence to pharyngitis management guidelines from the Infectious Diseases Society of America (IDSA), and nonantibiotic treatment. Results In the base-case analysis, reflecting current practice patterns, total expenditures were $1.2 billion with antibiotic resistance contributing 36% ($426 million). IDSA guideline adherence decreased costs to $559 million with resistance accounting for 6.8% ($37.9 million). Guideline adherence plus reducing office visits by 30% decreased costs to $372 million, with only 1.4% ($5.3 million) due to resistance. Additional cost-savings of $88 million were realized by using a nonantibiotic treatment strategy. Conclusions Current practice imposed a substantial economic burden on the payer, while guideline adherence resulted in cost reductions, especially in terms of resistance, emphasizing that antibiotic prescribing habits have broad economic consequences. Relevant stakeholders, payers, physicians, and other health-care providers should revisit efforts to encourage adherence to pharyngitis guidelines to reduce health-care costs. |
doi_str_mv | 10.1111/j.1524-4733.2007.00286.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754140106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1098301510605396</els_id><sourcerecordid>754140106</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5936-8f1c4f4256a66f81fad41b5fecdf44b629e66f99d770cd96a2eea55d7c2982523</originalsourceid><addsrcrecordid>eNqNkk1vEzEQhi0EoiXwF9Ce6Gm3ttefCJDaKlCkSkSicLUce0wdNrupnS3Nv8fbRCBxQPXFI_t9ZzyPB6GK4IaUdbpqCKesZrJtG4qxbDCmSjT3T9Dxn4unJcZa1S0m_Ai9yHmFMRYt5c_REVFEaiHZMXo_d0M_rKOrzsfkoa-GUJ35sdtWixubdv2PuI35bXV9A9XC7iCd5GoBKW_AbeMdvETPgu0yvDrsM_Tt4_z64rK--vLp88XZVe24bkWtAnEsMMqFFSIoEqxnZMkDOB8YWwqqoZxr7aXEzmthKYDl3EtHtaKctjN0ss-7ScPtCHlr1jE76DrbwzBmIzkjDJPS3gy9-a-SaKWlZKoI1V7o0pBzgmA2Ka5Ly4ZgM0E2KzOxNBNLM0E2D5DNfbG-PtQYl2vwf40HqkXwbi_4FTvYPTqx-X45L0Gxn-_tUJDeRUgmuwi9Ax9T4W78EB_zyA__JHFd7KOz3U_YQV4NY-rLlxliMjXYfJ1mZRqVAhHzVov2N4X4szk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19897748</pqid></control><display><type>article</type><title>Economic Burden of Adult Pharyngitis: The Payer's Perspective</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Salkind, Alan R., MD ; Wright, Julie M., PharmD</creator><creatorcontrib>Salkind, Alan R., MD ; Wright, Julie M., PharmD</creatorcontrib><description>Abstract Objectives Although not recommended by practice guidelines, physicians frequently prescribe an antibiotic for adults with viral pharyngitis. The financial burden of this practice, from the payer's perspective, has not been previously evaluated. The purpose of this study was to estimate those expenditures. Methods A cost-of-illness study was performed to estimate annual expenditures of pharyngitis management from the payer's perspective. National Ambulatory Care Survey data were used to represent current patterns of ambulatory care visits and antibiotic prescriptions for adult pharyngitis. Direct and antibiotic resistance costs were summed to estimate total expenditures for pharyngitis management. Resistance costs were calculated using a model linking the effect of antibiotic consumption to the cost consequences of resistant Streptococcus pneumoniae infection. Sensitivity analyses compared cost outcomes of current practice, adherence to pharyngitis management guidelines from the Infectious Diseases Society of America (IDSA), and nonantibiotic treatment. Results In the base-case analysis, reflecting current practice patterns, total expenditures were $1.2 billion with antibiotic resistance contributing 36% ($426 million). IDSA guideline adherence decreased costs to $559 million with resistance accounting for 6.8% ($37.9 million). Guideline adherence plus reducing office visits by 30% decreased costs to $372 million, with only 1.4% ($5.3 million) due to resistance. Additional cost-savings of $88 million were realized by using a nonantibiotic treatment strategy. Conclusions Current practice imposed a substantial economic burden on the payer, while guideline adherence resulted in cost reductions, especially in terms of resistance, emphasizing that antibiotic prescribing habits have broad economic consequences. Relevant stakeholders, payers, physicians, and other health-care providers should revisit efforts to encourage adherence to pharyngitis guidelines to reduce health-care costs.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1111/j.1524-4733.2007.00286.x</identifier><identifier>PMID: 18179674</identifier><language>eng</language><publisher>Malden, USA: Elsevier Inc</publisher><subject>Acute Disease ; Adherence ; Adult ; adults ; Ambulatory Care - economics ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - economics ; antibiotic resistance ; Antibiotics ; Burden ; Cohort Studies ; Cost of Illness ; cost-of-illness analysis ; Drug Resistance, Microbial ; Expenditure ; Guideline Adherence - statistics & numerical data ; Health Care Costs - statistics & numerical data ; Humans ; Internal Medicine ; Pharyngitis ; Pharyngitis - drug therapy ; Pharyngitis - economics ; Practice Patterns, Physicians' - statistics & numerical data ; Resistance</subject><ispartof>Value in health, 2008-07, Vol.11 (4), p.621-627</ispartof><rights>International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>2008 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>2007, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5936-8f1c4f4256a66f81fad41b5fecdf44b629e66f99d770cd96a2eea55d7c2982523</citedby><cites>FETCH-LOGICAL-c5936-8f1c4f4256a66f81fad41b5fecdf44b629e66f99d770cd96a2eea55d7c2982523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1524-4733.2007.00286.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1098301510605396$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,3537,27901,27902,30977,45550,45551,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18179674$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salkind, Alan R., MD</creatorcontrib><creatorcontrib>Wright, Julie M., PharmD</creatorcontrib><title>Economic Burden of Adult Pharyngitis: The Payer's Perspective</title><title>Value in health</title><addtitle>Value Health</addtitle><description>Abstract Objectives Although not recommended by practice guidelines, physicians frequently prescribe an antibiotic for adults with viral pharyngitis. The financial burden of this practice, from the payer's perspective, has not been previously evaluated. The purpose of this study was to estimate those expenditures. Methods A cost-of-illness study was performed to estimate annual expenditures of pharyngitis management from the payer's perspective. National Ambulatory Care Survey data were used to represent current patterns of ambulatory care visits and antibiotic prescriptions for adult pharyngitis. Direct and antibiotic resistance costs were summed to estimate total expenditures for pharyngitis management. Resistance costs were calculated using a model linking the effect of antibiotic consumption to the cost consequences of resistant Streptococcus pneumoniae infection. Sensitivity analyses compared cost outcomes of current practice, adherence to pharyngitis management guidelines from the Infectious Diseases Society of America (IDSA), and nonantibiotic treatment. Results In the base-case analysis, reflecting current practice patterns, total expenditures were $1.2 billion with antibiotic resistance contributing 36% ($426 million). IDSA guideline adherence decreased costs to $559 million with resistance accounting for 6.8% ($37.9 million). Guideline adherence plus reducing office visits by 30% decreased costs to $372 million, with only 1.4% ($5.3 million) due to resistance. Additional cost-savings of $88 million were realized by using a nonantibiotic treatment strategy. Conclusions Current practice imposed a substantial economic burden on the payer, while guideline adherence resulted in cost reductions, especially in terms of resistance, emphasizing that antibiotic prescribing habits have broad economic consequences. Relevant stakeholders, payers, physicians, and other health-care providers should revisit efforts to encourage adherence to pharyngitis guidelines to reduce health-care costs.</description><subject>Acute Disease</subject><subject>Adherence</subject><subject>Adult</subject><subject>adults</subject><subject>Ambulatory Care - economics</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - economics</subject><subject>antibiotic resistance</subject><subject>Antibiotics</subject><subject>Burden</subject><subject>Cohort Studies</subject><subject>Cost of Illness</subject><subject>cost-of-illness analysis</subject><subject>Drug Resistance, Microbial</subject><subject>Expenditure</subject><subject>Guideline Adherence - statistics & numerical data</subject><subject>Health Care Costs - statistics & numerical data</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Pharyngitis</subject><subject>Pharyngitis - drug therapy</subject><subject>Pharyngitis - economics</subject><subject>Practice Patterns, Physicians' - statistics & numerical data</subject><subject>Resistance</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNkk1vEzEQhi0EoiXwF9Ce6Gm3ttefCJDaKlCkSkSicLUce0wdNrupnS3Nv8fbRCBxQPXFI_t9ZzyPB6GK4IaUdbpqCKesZrJtG4qxbDCmSjT3T9Dxn4unJcZa1S0m_Ai9yHmFMRYt5c_REVFEaiHZMXo_d0M_rKOrzsfkoa-GUJ35sdtWixubdv2PuI35bXV9A9XC7iCd5GoBKW_AbeMdvETPgu0yvDrsM_Tt4_z64rK--vLp88XZVe24bkWtAnEsMMqFFSIoEqxnZMkDOB8YWwqqoZxr7aXEzmthKYDl3EtHtaKctjN0ss-7ScPtCHlr1jE76DrbwzBmIzkjDJPS3gy9-a-SaKWlZKoI1V7o0pBzgmA2Ka5Ly4ZgM0E2KzOxNBNLM0E2D5DNfbG-PtQYl2vwf40HqkXwbi_4FTvYPTqx-X45L0Gxn-_tUJDeRUgmuwi9Ax9T4W78EB_zyA__JHFd7KOz3U_YQV4NY-rLlxliMjXYfJ1mZRqVAhHzVov2N4X4szk</recordid><startdate>200807</startdate><enddate>200807</enddate><creator>Salkind, Alan R., MD</creator><creator>Wright, Julie M., PharmD</creator><general>Elsevier Inc</general><general>Blackwell Publishing Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7QJ</scope></search><sort><creationdate>200807</creationdate><title>Economic Burden of Adult Pharyngitis: The Payer's Perspective</title><author>Salkind, Alan R., MD ; Wright, Julie M., PharmD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5936-8f1c4f4256a66f81fad41b5fecdf44b629e66f99d770cd96a2eea55d7c2982523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acute Disease</topic><topic>Adherence</topic><topic>Adult</topic><topic>adults</topic><topic>Ambulatory Care - economics</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - economics</topic><topic>antibiotic resistance</topic><topic>Antibiotics</topic><topic>Burden</topic><topic>Cohort Studies</topic><topic>Cost of Illness</topic><topic>cost-of-illness analysis</topic><topic>Drug Resistance, Microbial</topic><topic>Expenditure</topic><topic>Guideline Adherence - statistics & numerical data</topic><topic>Health Care Costs - statistics & numerical data</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Pharyngitis</topic><topic>Pharyngitis - drug therapy</topic><topic>Pharyngitis - economics</topic><topic>Practice Patterns, Physicians' - statistics & numerical data</topic><topic>Resistance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salkind, Alan R., MD</creatorcontrib><creatorcontrib>Wright, Julie M., PharmD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salkind, Alan R., MD</au><au>Wright, Julie M., PharmD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Economic Burden of Adult Pharyngitis: The Payer's Perspective</atitle><jtitle>Value in health</jtitle><addtitle>Value Health</addtitle><date>2008-07</date><risdate>2008</risdate><volume>11</volume><issue>4</issue><spage>621</spage><epage>627</epage><pages>621-627</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>Abstract Objectives Although not recommended by practice guidelines, physicians frequently prescribe an antibiotic for adults with viral pharyngitis. The financial burden of this practice, from the payer's perspective, has not been previously evaluated. The purpose of this study was to estimate those expenditures. Methods A cost-of-illness study was performed to estimate annual expenditures of pharyngitis management from the payer's perspective. National Ambulatory Care Survey data were used to represent current patterns of ambulatory care visits and antibiotic prescriptions for adult pharyngitis. Direct and antibiotic resistance costs were summed to estimate total expenditures for pharyngitis management. Resistance costs were calculated using a model linking the effect of antibiotic consumption to the cost consequences of resistant Streptococcus pneumoniae infection. Sensitivity analyses compared cost outcomes of current practice, adherence to pharyngitis management guidelines from the Infectious Diseases Society of America (IDSA), and nonantibiotic treatment. Results In the base-case analysis, reflecting current practice patterns, total expenditures were $1.2 billion with antibiotic resistance contributing 36% ($426 million). IDSA guideline adherence decreased costs to $559 million with resistance accounting for 6.8% ($37.9 million). Guideline adherence plus reducing office visits by 30% decreased costs to $372 million, with only 1.4% ($5.3 million) due to resistance. Additional cost-savings of $88 million were realized by using a nonantibiotic treatment strategy. Conclusions Current practice imposed a substantial economic burden on the payer, while guideline adherence resulted in cost reductions, especially in terms of resistance, emphasizing that antibiotic prescribing habits have broad economic consequences. Relevant stakeholders, payers, physicians, and other health-care providers should revisit efforts to encourage adherence to pharyngitis guidelines to reduce health-care costs.</abstract><cop>Malden, USA</cop><pub>Elsevier Inc</pub><pmid>18179674</pmid><doi>10.1111/j.1524-4733.2007.00286.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1098-3015 |
ispartof | Value in health, 2008-07, Vol.11 (4), p.621-627 |
issn | 1098-3015 1524-4733 |
language | eng |
recordid | cdi_proquest_miscellaneous_754140106 |
source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Wiley Online Library Journals Frontfile Complete; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Acute Disease Adherence Adult adults Ambulatory Care - economics Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - economics antibiotic resistance Antibiotics Burden Cohort Studies Cost of Illness cost-of-illness analysis Drug Resistance, Microbial Expenditure Guideline Adherence - statistics & numerical data Health Care Costs - statistics & numerical data Humans Internal Medicine Pharyngitis Pharyngitis - drug therapy Pharyngitis - economics Practice Patterns, Physicians' - statistics & numerical data Resistance |
title | Economic Burden of Adult Pharyngitis: The Payer's Perspective |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T21%3A15%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Economic%20Burden%20of%20Adult%20Pharyngitis:%20The%20Payer's%20Perspective&rft.jtitle=Value%20in%20health&rft.au=Salkind,%20Alan%20R.,%20MD&rft.date=2008-07&rft.volume=11&rft.issue=4&rft.spage=621&rft.epage=627&rft.pages=621-627&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1111/j.1524-4733.2007.00286.x&rft_dat=%3Cproquest_cross%3E754140106%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19897748&rft_id=info:pmid/18179674&rft_els_id=S1098301510605396&rfr_iscdi=true |